VERU News and Press, Veru Inc. From 11/10/22

Veru Inc. ( NASDAQ: VERU ), a biopharma targeting cancer, shed ~65% of its value on Thursday pre-market after a group of independent experts at the FDA voted against granting the emergency use authorization (EUA) for its oral COVID-19 therapy sabizabulin. The sello...

MIAMI, FL, Nov. 09, 2022 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a biopharmaceutical company focused on developing novel medicines for COVID-19 and other viral ARDS-related diseases and for oncology, announces the results of today’s meeting of the U.S. Food and Drug Administrat...

Members of the FDA's Pulmonary-Allergy Drugs Advisory Committee voted 8-5 on Wednesday that the benefits of Veru's ( NASDAQ: VERU ) COVID-19 pill sabizabulin do not outweigh the risks. Veru ( VERU ) is seeking approval of the drug for hospitalized adults with COVID at ...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Pharmaceutical firm Veru (NASDAQ: VERU ) kicked off the first complete week of November with a bang as it delivered overall positive results regarding its Covid-19 therapeutic sabizabulin. Targeting the treatment of Cov...

Veru Inc. ( NASDAQ: VERU ), a biopharma targeting cancer, added 19% pre-market Monday as the company is set to face an FDA's Advisory Committee meeting this week regarding its marketing application for the oral COVID-19 therapy sabizabulin. The regulator is expected to...

MIAMI, Oct. 24, 2022 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a biopharmaceutical company focused on developing novel medicines for COVID-19 and other viral ARDS-related diseases and for oncology, today announced data from the late-breaker oral presentation of the Phase 3 trial of sabi...

Summary Veru's Sabizabulin generated some outstanding data in a Phase 3 clinical study evaluating it as a therapy for hospitalized COVID patients. Management appeared to believe an Emergency Use Authorization was a formality. The FDA has insisted on convening an Advisory Commi...

MIAMI, Oct. 13, 2022 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a biopharmaceutical company focused on developing novel medicines for COVID-19 and other viral ARDS-related diseases and for oncology, today announced that data from the Phase 3 trial of sabizabulin for hospitalized moderate...

Everyone's looking for safe harbors to park their cash amid a downwardly mobile market and globally fulminating economic turmoil. To merely beat the bear market, a stock needs to do better than lose nearly 20% of its value so far in 2022. The good news is that there are plenty of portfolio-...

Get ahead of the market by subscribing to Seeking Alpha's Stocks to Watch, a preview of key events scheduled for the coming week. The newsletter keeps you informed of the biggest stories set to make headlines, including upcoming IPOs, investor days, earnings reports and conference presentat...